Investing.com - Sutro Biopharma (NASDAQ: STRO) reported second quarter EPS of $-0.590, $0.20 better than the analyst estimate of $-0.792. Revenue for the quarter came in at $25.71M versus the consensus estimate of $21.02M.
Sutro Biopharma's stock price closed at $3.22. It is down -19.700% in the last 3 months and down -24.940% in the last 12 months.
Sutro Biopharma saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Sutro Biopharma's stock price’s past reactions to earnings here.
According to InvestingPro, Sutro Biopharma's Financial Health score is "fair performance".
Check out Sutro Biopharma's recent earnings performance, and Sutro Biopharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar